|Other Names||POU domain, class 2, transcription factor 2, Lymphoid-restricted immunoglobulin octamer-binding protein NF-A2, Octamer-binding protein 2, Oct-2, Octamer-binding transcription factor 2, OTF-2, POU2F2, OCT2, OTF2|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP13842a was selected from the N-term region of POU2F2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Transcription factor that specifically binds to the octamer motif (5'-ATTTGCAT-3'). Regulates transcription in a number of tissues in addition to activating immunoglobulin gene expression. Modulates transcription transactivation by NR3C1, AR and PGR. Isoform 5 activates the U2 small nuclear RNA (snRNA) promoter.|
|Cellular Location||Cytoplasm. Nucleus.|
|Tissue Location||Isoform 3 is B-cell specific. Isoform 5 is expressed in B-cells and the immunoglobulin-expressing T-cell line MOLT-4, but not in the T-cell line BW5147|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
POU2F2 is a transcription factor that specifically binds to the octamer motif (5'-ATTTGCAT-3'). Regulates transcription in a number of tissues in addition to activating immunoglobulin gene expression. Modulates transcription transactivation by NR3C1, AR and PGR. Isoform 5 activates the U2 small nuclear RNA (snRNA) promoter.
Galetti, M., et al. Biochem. Pharmacol. 80(2):179-187(2010)Bailey, S.D., et al. Diabetes Care (2010) In press :Advani, A.S., et al. Leuk. Lymphoma 51(4):606-612(2010)Talmud, P.J., et al. Am. J. Hum. Genet. 85(5):628-642(2009)Filipski, K.K., et al. Clin. Pharmacol. Ther. 86(4):396-402(2009)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.